Pages that link to "Q74753357"
Jump to navigation
Jump to search
The following pages link to Neomycin in the treatment of hepatic coma (Q74753357):
Displaying 19 items.
- The why and wherefore of hepatic encephalopathy (Q26771507) (← links)
- Therapeutic studies in hepatic encephalopathy (Q31130554) (← links)
- Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials (Q33200604) (← links)
- Treatment of chronic hepatic encephalopathy with levodopa (Q34476923) (← links)
- Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis (Q35790974) (← links)
- Oral neomycin dosage schedules for suppression of ammonia production by bowel flora (Q36484799) (← links)
- Update on the management of cirrhosis - focus on cost-effective preventative strategies (Q36784836) (← links)
- Pathophysiology and clinical basis of prevention and treatment of complications of chronic liver disease (Q37688812) (← links)
- Pharmacotherapy for hepatic encephalopathy (Q37762245) (← links)
- Hepatic encephalopathy: early diagnosis in pediatric patients with cirrhosis (Q38199095) (← links)
- Lactulose (Q39997360) (← links)
- Faecal ammonia and pH during lactulose administration in man: comparison with other cathartics (Q43250020) (← links)
- Extracorporeal methods of reducing high blood ammonia levels (Q43250859) (← links)
- Portocaval anastomosis as emergency treatment of massive bleeding from oesophageal varices (Q71117590) (← links)
- Medical Treatment of Portal Hypertension (Q71148404) (← links)
- High doses of neomycin sulfate and the absorption of glucose and xylose from the rat small intestine (Q72809307) (← links)
- Hyperammonemia and lactic acidosis in adults: Differential diagnoses with a focus on inborn errors of metabolism (Q87934488) (← links)
- Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives (Q92032230) (← links)
- Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view (Q94543861) (← links)